MX362869B - Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido. - Google Patents

Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido.

Info

Publication number
MX362869B
MX362869B MX2015006407A MX2015006407A MX362869B MX 362869 B MX362869 B MX 362869B MX 2015006407 A MX2015006407 A MX 2015006407A MX 2015006407 A MX2015006407 A MX 2015006407A MX 362869 B MX362869 B MX 362869B
Authority
MX
Mexico
Prior art keywords
preparation
dissolved oxygen
human albumin
reduced level
albumin
Prior art date
Application number
MX2015006407A
Other languages
English (en)
Other versions
MX2015006407A (es
Inventor
Nieto Juan Ignacio Jorquera
Fernandez Ana Maria Ortiz
Rierola Montserrat Costa
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX362869(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of MX2015006407A publication Critical patent/MX2015006407A/es
Publication of MX362869B publication Critical patent/MX362869B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención se refiere a un procedimiento de preparación de una solución de albúmina humana, más en particular, se refiere a un procedimiento que comprende una etapa de reducción del oxígeno disuelto en dicha solución de albúmina hasta una concentración igual o menor que 0,5 ppm. Con el procedimiento de la presente invención es posible obtener una solución de albúmina humana con un estado redox más cercano al estado redox de la albúmina presente en el plasma humano.
MX2015006407A 2014-05-29 2015-05-21 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido. MX362869B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430824A ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Publications (2)

Publication Number Publication Date
MX2015006407A MX2015006407A (es) 2015-11-30
MX362869B true MX362869B (es) 2019-02-20

Family

ID=52003454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006407A MX362869B (es) 2014-05-29 2015-05-21 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido.

Country Status (22)

Country Link
US (1) US10350274B2 (es)
EP (1) EP2952203B9 (es)
JP (3) JP2015224251A (es)
KR (1) KR101960729B1 (es)
CN (1) CN105315362B (es)
AR (1) AR100618A1 (es)
AU (1) AU2015202413B2 (es)
BR (1) BR102015012091A8 (es)
CA (1) CA2890642C (es)
CL (1) CL2015001446A1 (es)
ES (2) ES2524516B1 (es)
HU (1) HUE031823T2 (es)
IL (1) IL238898B (es)
MX (1) MX362869B (es)
MY (1) MY171771A (es)
NZ (1) NZ708537A (es)
PL (1) PL2952203T3 (es)
PT (1) PT2952203T (es)
RU (1) RU2657578C2 (es)
SG (1) SG10201504137PA (es)
TW (1) TWI607018B (es)
ZA (1) ZA201503539B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES2900302T3 (es) 2016-04-28 2022-03-16 Alkahest Inc Fracciones de plasma como terapia para el crecimiento y la progresión del tumor
KR20220107322A (ko) 2016-08-18 2022-08-02 알카헤스트 인코포레이티드 노화-관련된 인지 장애 치료제로서의 혈장 분획
BR112019022402A2 (pt) 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
CN109627322A (zh) * 2019-01-07 2019-04-16 中国科学院过程工程研究所 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094965A (en) * 1977-04-01 1978-06-13 New England Nuclear Corporation Diagnostic agents containing albumin and method for making same
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP4254117B2 (ja) * 2001-03-27 2009-04-15 ニプロ株式会社 アルブミン溶液収容プラスチック容器
EP1245217B1 (en) * 2001-03-27 2009-10-28 Nipro Corporation Plastic container containing albumin solution
WO2003002139A1 (fr) * 2001-06-29 2003-01-09 Asahi Kasei Kabushiki Kaisha Procede permettant d'ameliorer la stabilite de la preparation de proteines
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
EP1538151B1 (en) * 2003-08-28 2006-10-18 Nipro Corporation Artificial oxygen carrier and production method thereof
EP1986612B1 (en) * 2006-02-07 2012-09-12 Shire Human Genetic Therapies, Inc. Stabilized composition of glucocerebrosidase
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
CN102816230B (zh) * 2012-08-27 2014-02-12 同路生物制药股份有限公司 人血白蛋白的制备方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Also Published As

Publication number Publication date
NZ708537A (en) 2017-06-30
ES2601137T3 (es) 2017-02-14
JP2020111614A (ja) 2020-07-27
HUE031823T2 (en) 2017-08-28
RU2657578C2 (ru) 2018-06-14
US20150343025A1 (en) 2015-12-03
CN105315362B (zh) 2019-10-25
MY171771A (en) 2019-10-29
BR102015012091A2 (pt) 2016-01-05
EP2952203B9 (en) 2018-03-14
TWI607018B (zh) 2017-12-01
PL2952203T3 (pl) 2017-02-28
AR100618A1 (es) 2016-10-19
CA2890642A1 (en) 2015-11-29
CN105315362A (zh) 2016-02-10
AU2015202413A1 (en) 2015-12-17
KR101960729B1 (ko) 2019-03-21
ES2524516A1 (es) 2014-12-09
US10350274B2 (en) 2019-07-16
AU2015202413B2 (en) 2017-08-31
EP2952203B1 (en) 2016-10-26
BR102015012091A8 (pt) 2021-03-16
KR20160024348A (ko) 2016-03-04
IL238898B (en) 2018-01-31
SG10201504137PA (en) 2015-12-30
US20170000855A9 (en) 2017-01-05
RU2015118453A (ru) 2016-12-10
JP2018115210A (ja) 2018-07-26
TW201544510A (zh) 2015-12-01
ZA201503539B (en) 2017-01-25
CA2890642C (en) 2019-02-12
EP2952203A1 (en) 2015-12-09
ES2524516B1 (es) 2015-03-31
CL2015001446A1 (es) 2016-05-13
MX2015006407A (es) 2015-11-30
PT2952203T (pt) 2016-11-23
JP2015224251A (ja) 2015-12-14

Similar Documents

Publication Publication Date Title
EA033286B1 (ru) Способ лечения или отсрочки развития хронической болезни почек
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
NZ708537A (en) Method for the preparation of human albumin with reduced level of dissolved oxygen
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
PH12016500158A1 (en) Methods for controlling fucosylation levels in proteins
EA201791845A1 (ru) Твердые формы менахинолов
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
PH12016502322B1 (en) Compounds and methods for preventing or treating malaria
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
PH12016502150A1 (en) Method for treating renal cell carcimona
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MX2017003604A (es) Solucion de dialisis.
NZ722725A (en) Flavour stable beverages
MY188930A (en) Treatment process of gas containing zero-valent mercury and mercury separation system
EE05766B1 (et) Meetod suure aktiivkloorisisaldusega desinfektsioonivahendi saamiseks läbivoolu diafragmaelektrolüüserist
TH165188B (th) วิธีการสำหรับการเตรียมอัลบูมินมนุษย์ที่มีระดับของออกซิเจนที่ได้ละลายอยู่ลดลง
MX361559B (es) Metodo para tratar limo de anodo de plomo.
UY36507A (es) Procedimiento de preparacion de albumina humana con nivel de oxigeno disuelto reducido
UA79303U (ru) Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний
TH165188A (th) วิธีการสำหรับการเตรียมอัลบูมินมนุษย์ที่มีระดับของออกซิเจนที่ได้ละลายอยู่ลดลง
UA105659U (uk) Застосування способу визначення вмісту теофіліну як способу визначення концентрації елетриптану у водному розчині
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
UA91071U (uk) Спосіб профілактики та корекції запальних хвороб на донозологічному рівні
GB2546703A (en) Compounds

Legal Events

Date Code Title Description
FG Grant or registration